Since then, others have been developed including measurement of HER2 levels prior to treatment of breast cancer with the anti-HER2 antibody pertuzumab, and measurement of PD-L1 levels prior to treatment with the anti-PD-L1 antibody pembrolizumab (Jørgensen et al., 2016). This evidence concerns the gene ERBB2 and breast cancer.